-
High-quality evidence from registry-based studies
High-quality evidence from registry-based studies
-
High-quality evidence from registry-based studies
High-quality evidence from registry-based studies
EMA publishes guidance to provide key methods and good regulatory practices to pharmaceutical organisations on planning and conduct of registry-based studies
-
EMA recommendation on Spikevax booster
EMA recommendation on Spikevax booster
-
EMA recommendation on Spikevax booster
EMA recommendation on Spikevax booster
EMA concludes that a booster dose of the COVID-19 vaccine Spikevax may be considered in people aged 18 years and above
-
New application for COVID-19 treatment
New application for COVID-19 treatment
-
New application for COVID-19 treatment
New application for COVID-19 treatment
EMA starts a rolling review of molnupiravir, an oral antiviral medicine developed for the treatment of COVID-19 in adults
-
New manufacturing sites, formulation for Comirnaty
New manufacturing sites, formulation for Comirnaty
-
New manufacturing sites, formulation for Comirnaty
New manufacturing sites, formulation for Comirnaty
EMA approves two additional manufacturing sites and a ready-to-use formulation for Comirnaty, the COVID-19 vaccine developed by BioNTech / Pfizer.
